Overview

A Study to Evaluate Safety and Efficacy of Caelyx in Combination With Cyclophosphamide in the Treatment of Metastatic Breast Cancer (P02948)

Status:
Completed

Trial end date:
2007-08-01

Target enrollment:

Participant gender:

Summary

Women with metastatic breast cancer are usually treated with anthracyclines (ie, doxorubicin or epirubicin) but cardiac toxicity limits their use. The aim of this study is to evaluate the safety and efficacy of Caelyx in combination with cyclophosphamide in women with metastatic breast cancer who have received adjuvant anthracyclines with or without a taxane.

Phase:

Phase 2

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Collaborator:

Princess Margaret Hospital, Canada

Treatments:

Cyclophosphamide
Doxorubicin
Liposomal doxorubicin